Law Professor Says Valeant / Ackman Model For Acquisitions Is Dead

The much discussed Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) / Pershing Square model for bidder / activist collaboration is dead, according to an article posted on the Harvard University Law School blog. The article, posted by Philip Richter*, a guest contributor on the Harvard Law School’s Corporate Governance and Financial regulation blog, an Adjunct Professor of Law at New York University and a senior counsel at the law firm of Fried Frank, Harris, Shriver & Jacobson LLP, wrote an apparent obituary for the controversial, some said illegal, practice. Valeant Pharmaceuticals’ failed pursuit of Allergan Noting that the distinguishing feature of Valeant…